Chan, Chang-Yien http://orcid.org/0000-0001-5841-1417
Resontoc, Lourdes Paula
Qader, Md Abdul
Chan, Yiong-Huak
Liu, Isaac Desheng
Lau, Perry Yew-Weng
Than, Mya
Yeo, Wee-Song
Loh, Alwin Hwai-Liang
Tan, Puay-Hoon
Wei, Changli
Reiser, Jochen
Biswas, Subhra K.
Ng, Kar-Hui
Yap, Hui-Kim
Article History
Received: 10 June 2018
Revised: 24 December 2018
Accepted: 27 December 2018
First Online: 15 January 2019
Competing interests
: J.R. is inventor on pending and issued patents related to antiproteinuric therapies targeting suPAR. He stands to gain royalties from present and future commercialization. He is also cofounder and advisor to TRISAQ, a biotechnology company. C.W. has a pending patent on suPAR in diabetes. He stands to gain royalties from future commercialization products concerning this application. The other authors declare no competing interests.